文献速递耳科与耳神经头颈外科

头颈癌放疗与顺铂化疗后听力损失的预测模型

Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2020-01-01

该回顾性队列研究纳入242例(482耳)接受放疗和/或顺铂化疗的头颈癌患者,利用治疗前可获取的信息构建多变量混合模型预测治疗后纯音平均听阈。模型固定效应预测可解释77%的变异,预测治疗后纯音平均听阈大于35 dB的灵敏度为80%、特异度为75%,AUC为0.85。

要点

  • 治疗前信息可构建模型预测头颈癌治疗后听力损失。
  • 模型对治疗后纯音平均听阈大于35 dB预测AUC为0.85。
  • 耳蜗放疗与顺铂暴露与听力损失相关。

核心结论

  • 开发出首个可在治疗前临床使用的头颈癌治疗后听力预测模型。
  • 耳蜗暴露于顺铂化疗和放疗与头颈癌患者听力损失相关。

研究设计与样本

  • 回顾性队列研究, tertiary academic medical center,纳入242例(482耳)头颈癌患者,2014年10月1日至2018年7月31日接受放疗和/或顺铂治疗且有随访听力数据。
  • 所有患者接受放疗,105例(43.4%)接受顺铂化疗。
  • 采用多变量混合模型,仅使用治疗开始时临床医生可获取的信息预测治疗后纯音平均听阈。

主要发现

  • 242例患者中56例女性、186例男性,平均(SD)年龄60(10)岁。
  • 顺铂累积剂量平均(SD)298(109)mg/m2;耳蜗放疗剂量平均(SD)15(13)Gy。
  • 模型固定效应预测与治疗后纯音平均听阈变异的77%(95%CI,73%-81%)一致。
  • 预测治疗后纯音平均听阈大于35 dB的灵敏度80%、特异度75%,AUC 0.85。

关键数值与推荐

  • 预测模型固定效应解释治疗后纯音平均听阈变异77%(95%CI,73%-81%)。
  • 预测治疗后纯音平均听阈大于35 dB:灵敏度80%,特异度75%,AUC 0.85。

临床怎么用

  • 可在治疗开始前使用治疗前信息预测头颈癌患者放疗和/或顺铂化疗后听力损失,辅助患者知情决策。

局限性

  • 回顾性队列研究,仅纳入有随访听力数据的患者。
  • 单中心研究,样本来自三级学术医疗中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Accurate, accessible predictions of posttreatment hearing loss for patients with head and neck cancer prior to the initiation of treatment are a necessary part of informed patient decision-making. OBJECTIVE: To develop a prediction model for postradiotherapy and/or post-cisplatin chemotherapy hearing loss for patients with head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted at a tertiary academic medical center among 242 patients (482 ears) with head and neck cancer who were treated with radiotherapy and/or cisplatin from October 1, 2014, to July 31, 2018, and had follow-up audiometric data available. EXPOSURES: Radiotherapy and cisplatin chemotherapy. MAIN OUTCOMES AND MEASURES: Patient hearing level, as measured by the mean of pure tone audiometry at 1, 2, and 4 kHz on completion of treatment. A multivariable mixed model for predicting the posttreatment pure tone average was developed using only information available to clinicians at the beginning of treatment. RESULTS: A total of 242 patients (482 ears; 56 women and 186 men; mean [SD] age, 60 [10] years) were included in the analysis. All patients in the study received radiotherapy, and 105 (43.4%) received cisplatin chemotherapy. The mean (SD) total cumulative cisplatin dose was 298 (109) mg/m2. Patients' ears received a mean (SD) cochlear radiotherapy dose of 15 (13) Gy. The fixed-effects predictions from the predictive model agreed with 77% (95% CI, 73%-81%) of the variability in the posttreatment pure tone average. This predictive model also had a sensitivity of 80% and a specificity of 75% for predicting an observed posttreatment pure tone average greater than 35 dB (area under the receiver operating characteristic curve, 0.85). CONCLUSIONS AND RELEVANCE: To our knowledge, this study develops the first accurate prediction model of posttreatment hearing in patients with head and neck cancer that is feasible for use in the clinical setting before the initiation of treatment. This research confirms that exposure of the cochlea to cisplatin chemotherapy and radiotherapy is associated with hearing loss in patients with head and neck cancer. Finally, this research motivates future studies of ototoxic effects to better understand the adverse effects of head and neck cancer treatment.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Schuette A, Lander DP, Kallogjeri D, et al. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2020. PMID: 31750863. doi:10.1001/jamaoto.2019.3550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。